Cardinal Health completes acquisition of Cordis

8th October 2015

398

Cardinal Health has announced that it has completed the acquisition of Johnson & Johnson’s Cordis business for US $1.944 billion. Planning has been ongoing since the acquisition announcement in early March 2015, and the integration is off to a successful start with management teams in place worldwide. With the Cardinal Health acquisition of Cordis, devices such as the Cordis S.M.A.R.T Vascular Stent Systems are now part of the Cardinal Health portfolio.

A press release reports that collectively, Cardinal Health and Cordis will now be able to offer a multi-dimensional set of solutions that will become increasingly important with healthcare’s emerging value-based payment models. It adds that the acquisition of Cordis will strengthen Cardinal Health’s portfolio of physician preference items, which include offerings in the cardiovascular, wound management, and orthopaedics areas. The company is helping customers standardise around medical devices, while offering innovative solutions in supply chain management, inventory optimisation, and work flow tools and data to support the most effective management of the patient.

Collectively, Cardinal Health and Cordis will now be able to offer high-quality, daily-use products; reliable, trackable inventory and logistics; and deep analytic capabilities that will result in a comprehensive offering for the entire episode of care. This multi-dimensional set of solutions will become increasingly important with emerging value-based payment models.

As previously announced, Cardinal Health expects the acquisition to be slightly dilutive to its fiscal 2016 non-GAAP diluted earnings per share (EPS) from continuing operations. The company expects fiscal 2017 accretion in non-GAAP diluted EPS of greater than US $0.20 per share, inclusive of the cost of an incremental US $0.07-$0.08 per share of interest expense associated with transaction financing, and for the acquisition to be increasingly accretive thereafter. The company continues to assume that synergies will exceed $100 million annually exiting fiscal 2018.

George Barrett, chairman and CEO of Cardinal Health, says: “I am extremely pleased to welcome our new Cordis colleagues to Cardinal Health. With an aging population and the accompanying demand for less invasive medical treatments, health systems around the world are searching for the best ways to ensure the highest quality care in the most cost-effective way.”

In recognition of its strong brand equity, Cordis products will continue to be sold under the Cordis brand name, but with a logo that identifies Cordis as a Cardinal Health company.